Adenohypophyseal tumors, which were recently renamed pituitary neuroendocrine tumors
(PitNET), are mostly benign, but may present various behaviors: invasive,“aggressive” and …

This review summarizes the changes in the 5th Edition of the WHO Classification of
Endocrine and Neuroendocrine Tumors that relate to the pituitary gland. The new …

Abstract The 2017 World Health Organization (WHO) classification proposes to type and
subtype primary adenohypophyseal tumours according to their cell lineages with the aim to …

The classification of adenohypophysial neoplasms as “pituitary neuroendocrine
tumors”(PitNETs) was proposed in 2017 to reflect their characteristics as epithelial …

The latest edition of the WHO classification of the central nervous system was published in
2021. This review summarizes the major revisions to the classification of anterior pituitary …

This review focuses on discussing the main changes on the upcoming fourth edition of the
WHO Classification of Tumors of the Pituitary Gland emphasizing histopathological and …

Recent studies have reported the prevalence of pituitary tumors to be~ 1/1000 population.
Many are prolactin-producing tumors that are managed medically, however, the …

In the 2022 fifth edition of the WHO Classification of Endocrine Tumours and of Central
Nervous System Tumours, pituitary adenomas are reclassified as neuroendocrine tumours …

Background Most pituitary neuroendocrine tumors (PitNETs) show benign behavior, but a
substantial number are invasive, recur, or resist medical treatment. Based on a retrospective …

Non-functioning pituitary neuroendocrine tumors do not cause endocrine symptoms related
to hypersecretion of adenohypophyseal hormones and are clinically characterized by …